Humacyte to Seek Israeli Approval for Symvess in Vascular Trauma Repair
I'm PortAI, I can summarize articles.
Humacyte Inc. plans to file a Marketing Authorization Application with the Israel Ministry of Health for its acellular tissue engineered vessel, Symvess, aimed at arterial trauma repair by Q1 2026. The review is expected to take 120 working days, leveraging its existing FDA approval. The company is collaborating with Israeli surgeons from the V005 Phase 2/3 trial for product access. The FDA approved Humacyte's Biologics License Application for ATEV in vascular trauma in December 2024.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments